EMA Authorised: Voriconazole Hikma (previously Voriconazole Hospira) (voriconazole) — Hikma Farmaceutica (Portugal) S.A.

View source ↗

Summary

The EMA authorised Voriconazole Hikma for fungal infections, including aspergillosis and candidiasis, with Hikma Farmaceutica (Portugal) S.A. as the marketing a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis

Drugs mentioned

• Voriconazole Hikma (voriconazole)

Snippet

Status: Authorised. Therapeutic area: Bacterial Infections and Mycoses;Aspergillosis;Candidiasis. MAH: Hikma Farmaceutica (Portugal) S.A.. Decision date: 22/12/2025